Trainee Milestones and Updates
William Puszyk, PhD
Department of Pathology, Immunology, and Laboratory Medicine
University of Florida
Gestational diabetes impairs Nrf2-mediated adaptive antioxidant defenses and redox signaling in fetal endothelial cells in utero.
Cheng X, Chapple SJ, Patel B, Puszyk W, Sugden D, Yin X, Mayr M, Siow RC, Mann GE. Diabetes. 2013 Sep 5. [Epub ahead of print]
Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma.
Puszyk WM, Trinh TL, Chapple SJ, Liu C.
Lab Invest. 2013 Sep;93(9):983-90. doi: 10.1038/labinvest.2013.94. Epub 2013 Aug 5.
The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells.
Puszyk W, Down T, Grimwade D, Chomienne C, Oakey RJ, Solomon E, Guidez F.
EMBO J. 2013 Jul 3;32(13):1941-52. doi: 10.1038/emboj.2013.118. Epub 2013 May 31.
Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.
Ogunwobi OO, Puszyk W, Dong HJ, Liu C.
PLoS One. 2013 May 28;8(5):e63765. doi: 10.1371/journal.pone.0063765. Print 2013.
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Zhao X, Tian C, Puszyk WM, Ogunwobi OO, Cao M, Wang T, Cabrera R, Nelson DR, Liu C.
Lab Invest. 2013 Jan;93(1):8-19. doi: 10.1038/labinvest.2012.144. Epub 2012 Oct 29.
Andrei Turtoi, PhD
Laboratory of Metastasis Research
University of Liege
Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies.
Turtoi A, Blomme A, Debois D, Somja J, Delvaux D, Patsos G, Di Valentin E, Peulen O, Mutijima EN, De Pauw E, Delvenne P, Detry O, Castronovo V. Hepatology. 2013 Jul 6. doi: 10.1002/hep.26608. [Epub ahead of print] PMID: 23832580 [PubMed - as supplied by publisher]
"At the University of Liege, I am taking part in translational cancer research with focus on discovery of novel proteins for targeted therapies. We have specific interest in understanding why today’s targeted therapies fail in the heterogeneous tumor environment. Recently we have published a study where we have characterized the proteomic heterogeneity in colorectal cancer liver metastasis. We have surprisingly found a pattern of antigen expression that can now be used to more effectively organize targeted therapy approaches in patients."
Myoferlin is a key regulator of EGFR activity in breast cancer.
Turtoi A, Blomme A, Bellahcène A, Gilles C, Hennequière V, Peixoto P, Bianchi E, Noel A, De Pauw E, Lifrange E, Delvenne P, Castronovo V. Cancer Res. 2013 Sep 1;73(17):5438-48. doi: 10.1158/0008-5472.CAN-13-1142. Epub 2013 Jul 17. PMID: 23864327 [PubMed - in process]
"We have also recently discovered and patented a new tumor-enriched membrane protein, called myoferlin, which has the potential to be used as novel, effective therapeutic target in several different cancers (breast, pancreas, colon etc.). We have been recently able to shed light on the fully unknown role of this protein in cancer. Namely, myoferlin is a key factor that controls the function of EGFR, participating in the proper internalization and degradation of the receptor. Considering the therapeutic significance of EGFR targeting, our findings identify myoferlin as an novel candidate function to target for future drug development."